» Articles » PMID: 29107454

Prevalence of Micro- and Macrovascular Diabetes Complications at Time of Type 2 Diabetes Diagnosis and Associated Clinical Characteristics: A Cross-sectional Baseline Study of 6958 Patients in the Danish DD2 Cohort

Overview
Specialty Endocrinology
Date 2017 Nov 7
PMID 29107454
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: To examine the prevalence of micro- and macrovascular complications and their associated clinical characteristics at time of type 2 diabetes (T2D) diagnosis.

Methods: We examined the prevalence of complications and associated clinical characteristics among 6958 newly diagnosed T2D patients enrolled in the prospective Danish Center for Strategic Research in T2D cohort during 2010-2016. We calculated age- and gender-adjusted prevalence ratios (aPRs) of complications using log-binomial and Poisson regression.

Results: In total, 35% (n=2456) T2D patients had diabetic complications around diagnosis; 12% (n=828) had microvascular complications, 17% (n=1186) macrovascular complications, and 6% (n=442) had both. HbA1c levels of ≥7% were associated with microvascular complications [HbA1c 7%-8%; aPR: 1.35, 95% confidence interval (CI): 1.12-1.62] but not macrovascular complications [aPR: 0.91, 95% CI: 0.76-1.08]. High C-peptide≥800pmol/L was associated with macrovascular [aPR 1.34, 95% CI: 1.00-1.80] but not microvascular [aPR 0.97, 95% CI: 0.71-1.33] complications. Macrovascular complications were associated with male sex, age>50years, obesity, hypertriglyceridemia, low HDL cholesterol, smoking, elevated CRP levels, and anti-hypertensive therapy. Microvascular complications were associated with high blood pressure, hypertriglyceridemia, and absence of lipid-lowering therapy.

Conclusions: One-third of patients with T2D had diabetes complications around time of diagnosis. Our findings suggest different pathophysiological mechanisms behind micro- and macrovascular complications.

Citing Articles

The Impact of Virtual Consultations on Quality of Care for Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis.

Aldakhil R, Greenfield G, Lammila-Escalera E, Laranjo L, Hayhoe B, Majeed A J Diabetes Sci Technol. 2025; :19322968251316585.

PMID: 39960237 PMC: 11833803. DOI: 10.1177/19322968251316585.


Nailfold capillary abnormalities as indicators of diabetic nephropathy progression: a cross-sectional study in type 2 diabetes.

Hsu P, Liao P, Huang S, Chang H, Chiang J, Lo L Ann Med. 2025; 57(1):2458766.

PMID: 39898556 PMC: 11792153. DOI: 10.1080/07853890.2025.2458766.


Insights into the molecular underpinning of type 2 diabetes complications.

Singh A, Bocher O, Zeggini E Hum Mol Genet. 2025; 34(6):469-480.

PMID: 39807636 PMC: 11891870. DOI: 10.1093/hmg/ddae203.


Impact of virtual consultations on quality of care in type 2 diabetes: a systematic review and narrative synthesis protocol.

Aldakhil R, Lammila-Escalera E, Hayhoe B, Majeed A, Greenfield G, Neves A BMJ Open. 2024; 14(11):e082452.

PMID: 39488411 PMC: 11535670. DOI: 10.1136/bmjopen-2023-082452.


Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients (Diabetes Metab J 2024;48:253-64).

Lee E Diabetes Metab J. 2024; 48(5):1005-1007.

PMID: 39313233 PMC: 11449823. DOI: 10.4093/dmj.2024.0417.